#7: TheMachine: ACHN Stock News : Achillion Granted U.S. Patent for NS4A Antagonists in Hepatitis C
Receives Novel Mechanism of Action Claims as Inhibitor of... |
May 25, 2009
05:49:10 PM |
#6: TheMachine: ACHN Stock News : Achillion Announces Appointment of New Head of Business Development
NEW HAVEN, Conn., Jan. 7, 2009 (GLOBE NEWSWIRE) -- Achillion
... |
February 8, 2009
12:52:35 AM |
#5: TheMachine: Achillion Appoints Nicholas Simon to Board of Directors
NEW HAVEN, Conn., Aug. 20, 2008 (GLOBE NEWSWIRE) -- Achillion
... |
September 20, 2008
01:03:11 AM |
#4: Stock News Bot: Achillion and FOB Synthesis Announce Collaboration for the Development of Carbapenem Compounds
Achillion and FOB Synthesis Announce... |
April 13, 2008
03:49:15 PM |
#3: TheMachine: New Data for Achillion's Elvucitabine Demonstrate Drug's Safety, Efficacy and Suitability for Combination Therapy in HIV-Infected Patients
NEW HAVEN, Conn., Jan. 31,... |
February 10, 2008
06:21:23 AM |
#2: FastFun: Achillion Reports Safety and Potent Antiviral Activity in Topline Results From Elvucitabine Phase 2 Study in HIV-Infected Patients
NEW HAVEN, Conn., Oct. 15, 2007 (PRIME NEWSWIRE) -- Achillion... |
October 15, 2007
11:50:48 PM |
#1: Jason: ACHN, Achillion Announces the Resignation of John C. Pottage, Jr., M.D., Senior Vice President and Chief Medical Officer
Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN Stock Forum) today announced that... |
June 4, 2007
08:23:18 AM |
